 Jeanelle Sheeder
Concepts (614)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contraception | 18 | 2023 | 117 | 7.270 |
Why?
| | Contraceptive Agents, Female | 23 | 2023 | 64 | 4.010 |
Why?
| | Family Planning Services | 12 | 2023 | 68 | 3.580 |
Why?
| | Contraceptive Agents | 7 | 2023 | 54 | 3.330 |
Why?
| | Contraception Behavior | 18 | 2023 | 81 | 3.290 |
Why?
| | Pregnancy in Adolescence | 17 | 2015 | 80 | 3.160 |
Why?
| | Desogestrel | 19 | 2023 | 40 | 2.700 |
Why?
| | Pregnancy | 73 | 2023 | 5517 | 2.370 |
Why?
| | Long-Acting Reversible Contraception | 8 | 2023 | 24 | 2.270 |
Why?
| | Abortion, Induced | 12 | 2023 | 71 | 2.020 |
Why?
| | Prenatal Care | 9 | 2020 | 253 | 2.000 |
Why?
| | Hospitals, Religious | 5 | 2020 | 5 | 1.740 |
Why?
| | Counseling | 6 | 2020 | 342 | 1.650 |
Why?
| | Female | 160 | 2023 | 59466 | 1.600 |
Why?
| | Intrauterine Devices | 7 | 2019 | 24 | 1.580 |
Why?
| | Drug Implants | 17 | 2023 | 70 | 1.570 |
Why?
| | Gynecology | 10 | 2023 | 163 | 1.490 |
Why?
| | Adolescent | 84 | 2023 | 17831 | 1.470 |
Why?
| | Adolescent Behavior | 9 | 2015 | 489 | 1.450 |
Why?
| | Postpartum Period | 10 | 2022 | 278 | 1.430 |
Why?
| | Young Adult | 61 | 2023 | 10455 | 1.410 |
Why?
| | Pregnancy Outcome | 8 | 2021 | 337 | 1.240 |
Why?
| | Reproductive Health | 4 | 2023 | 71 | 1.210 |
Why?
| | Endometrial Neoplasms | 10 | 2022 | 141 | 1.200 |
Why?
| | Humans | 176 | 2023 | 114624 | 1.150 |
Why?
| | Catholicism | 5 | 2020 | 9 | 1.150 |
Why?
| | Colorado | 33 | 2023 | 4099 | 1.060 |
Why?
| | Obstetrics | 7 | 2023 | 146 | 1.040 |
Why?
| | Contraceptives, Oral, Combined | 2 | 2023 | 16 | 1.000 |
Why?
| | Patient Acceptance of Health Care | 3 | 2020 | 681 | 0.980 |
Why?
| | Adult | 86 | 2023 | 30528 | 0.980 |
Why?
| | Postnatal Care | 3 | 2021 | 65 | 0.950 |
Why?
| | Health Knowledge, Attitudes, Practice | 10 | 2020 | 1183 | 0.940 |
Why?
| | Sexual Behavior | 7 | 2022 | 440 | 0.880 |
Why?
| | Patient Satisfaction | 5 | 2023 | 578 | 0.870 |
Why?
| | Enoxaparin | 2 | 2020 | 52 | 0.860 |
Why?
| | Pyridones | 2 | 2020 | 123 | 0.820 |
Why?
| | Cross-Sectional Studies | 22 | 2023 | 4405 | 0.810 |
Why?
| | Adolescent Health Services | 3 | 2020 | 68 | 0.810 |
Why?
| | Religion and Medicine | 3 | 2020 | 25 | 0.800 |
Why?
| | Levonorgestrel | 4 | 2018 | 31 | 0.720 |
Why?
| | Mothers | 5 | 2022 | 651 | 0.710 |
Why?
| | Pyrazoles | 2 | 2020 | 362 | 0.710 |
Why?
| | Pregnant Women | 2 | 2019 | 131 | 0.700 |
Why?
| | Parity | 5 | 2016 | 98 | 0.700 |
Why?
| | Venous Thromboembolism | 2 | 2020 | 231 | 0.690 |
Why?
| | Surveys and Questionnaires | 23 | 2023 | 4620 | 0.690 |
Why?
| | Group Processes | 2 | 2018 | 53 | 0.690 |
Why?
| | Hysterectomy | 6 | 2019 | 106 | 0.680 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 74 | 0.680 |
Why?
| | Religion and Psychology | 1 | 2019 | 24 | 0.670 |
Why?
| | Ovarian Neoplasms | 6 | 2020 | 388 | 0.670 |
Why?
| | Sex Offenses | 1 | 2022 | 148 | 0.650 |
Why?
| | Patient-Centered Care | 2 | 2021 | 473 | 0.650 |
Why?
| | Pregnancy Rate | 2 | 2017 | 55 | 0.650 |
Why?
| | Rural Health Services | 1 | 2019 | 92 | 0.640 |
Why?
| | Vulnerable Populations | 1 | 2020 | 133 | 0.630 |
Why?
| | Financial Support | 1 | 2018 | 18 | 0.610 |
Why?
| | Health Care Sector | 1 | 2018 | 24 | 0.610 |
Why?
| | Intrauterine Devices, Copper | 5 | 2018 | 7 | 0.610 |
Why?
| | Pregnancy, Unplanned | 3 | 2017 | 33 | 0.610 |
Why?
| | Fibrinolytic Agents | 1 | 2020 | 234 | 0.600 |
Why?
| | Community Health Services | 1 | 2019 | 212 | 0.590 |
Why?
| | Prosthesis Implantation | 2 | 2017 | 138 | 0.580 |
Why?
| | Health Services Accessibility | 3 | 2022 | 761 | 0.580 |
Why?
| | Retrospective Studies | 32 | 2023 | 12542 | 0.560 |
Why?
| | Luteal Phase | 1 | 2017 | 41 | 0.550 |
Why?
| | Delivery of Health Care | 2 | 2023 | 833 | 0.550 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 125 | 0.550 |
Why?
| | Intrauterine Devices, Medicated | 6 | 2017 | 23 | 0.550 |
Why?
| | Parenting | 1 | 2020 | 252 | 0.540 |
Why?
| | Lacerations | 3 | 2022 | 27 | 0.530 |
Why?
| | Interprofessional Relations | 1 | 2018 | 249 | 0.520 |
Why?
| | Ambulatory Care Facilities | 4 | 2019 | 213 | 0.520 |
Why?
| | Depression, Postpartum | 3 | 2020 | 103 | 0.510 |
Why?
| | Health Personnel | 1 | 2021 | 574 | 0.500 |
Why?
| | Genital Neoplasms, Female | 4 | 2020 | 70 | 0.500 |
Why?
| | Guatemala | 3 | 2021 | 266 | 0.500 |
Why?
| | Group Structure | 1 | 2015 | 1 | 0.500 |
Why?
| | Risk | 2 | 2017 | 812 | 0.490 |
Why?
| | Perimenopause | 1 | 2015 | 61 | 0.490 |
Why?
| | Carcinoma, Endometrioid | 3 | 2022 | 46 | 0.480 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2019 | 1214 | 0.480 |
Why?
| | Multicenter Studies as Topic | 1 | 2015 | 248 | 0.470 |
Why?
| | Fertility Preservation | 3 | 2023 | 46 | 0.470 |
Why?
| | Uterus | 1 | 2015 | 192 | 0.470 |
Why?
| | Patient Selection | 3 | 2015 | 641 | 0.470 |
Why?
| | Safety-net Providers | 1 | 2015 | 95 | 0.460 |
Why?
| | Intention | 4 | 2018 | 144 | 0.450 |
Why?
| | Middle Aged | 39 | 2022 | 26719 | 0.440 |
Why?
| | Maternal Age | 3 | 2018 | 117 | 0.440 |
Why?
| | Primary Health Care | 4 | 2023 | 1512 | 0.440 |
Why?
| | Goals | 1 | 2014 | 147 | 0.420 |
Why?
| | Internship and Residency | 6 | 2023 | 926 | 0.420 |
Why?
| | Attitude to Health | 3 | 2020 | 405 | 0.410 |
Why?
| | Estradiol | 1 | 2015 | 455 | 0.410 |
Why?
| | Mass Screening | 8 | 2023 | 1004 | 0.410 |
Why?
| | Choice Behavior | 3 | 2019 | 155 | 0.410 |
Why?
| | Postoperative Complications | 9 | 2020 | 2128 | 0.410 |
Why?
| | Papillomavirus Vaccines | 1 | 2015 | 223 | 0.410 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2021 | 216 | 0.400 |
Why?
| | Premature Birth | 1 | 2015 | 276 | 0.390 |
Why?
| | Obstetric Labor Complications | 2 | 2022 | 30 | 0.370 |
Why?
| | United States | 19 | 2021 | 12176 | 0.370 |
Why?
| | Feasibility Studies | 7 | 2022 | 739 | 0.370 |
Why?
| | Magnetoencephalography | 13 | 2000 | 104 | 0.360 |
Why?
| | Socioeconomic Factors | 5 | 2021 | 1077 | 0.350 |
Why?
| | Disclosure | 2 | 2022 | 101 | 0.340 |
Why?
| | Robotic Surgical Procedures | 3 | 2016 | 85 | 0.340 |
Why?
| | Functional Laterality | 11 | 2001 | 198 | 0.340 |
Why?
| | Health Behavior | 1 | 2015 | 704 | 0.340 |
Why?
| | Nurse Midwives | 2 | 2020 | 29 | 0.340 |
Why?
| | Lymph Nodes | 3 | 2018 | 419 | 0.340 |
Why?
| | Communication | 3 | 2022 | 744 | 0.330 |
Why?
| | Evoked Potentials, Auditory | 10 | 2001 | 171 | 0.320 |
Why?
| | Birth Intervals | 2 | 2019 | 16 | 0.320 |
Why?
| | Chlamydia trachomatis | 2 | 2007 | 36 | 0.320 |
Why?
| | Condoms | 3 | 2017 | 113 | 0.320 |
Why?
| | Life Style | 3 | 2021 | 430 | 0.320 |
Why?
| | Patient Participation | 1 | 2012 | 359 | 0.310 |
Why?
| | Intrauterine Device Expulsion | 3 | 2017 | 6 | 0.300 |
Why?
| | Chlamydia Infections | 2 | 2007 | 65 | 0.300 |
Why?
| | Infant, Small for Gestational Age | 2 | 2019 | 76 | 0.300 |
Why?
| | Women's Health | 2 | 2020 | 271 | 0.300 |
Why?
| | Cohort Studies | 11 | 2021 | 4894 | 0.290 |
Why?
| | Pregnancy Complications | 4 | 2019 | 429 | 0.290 |
Why?
| | Attitude | 3 | 2019 | 229 | 0.290 |
Why?
| | Vaccination | 1 | 2015 | 1204 | 0.290 |
Why?
| | Male | 42 | 2022 | 55555 | 0.280 |
Why?
| | Time Factors | 11 | 2019 | 6112 | 0.280 |
Why?
| | Uterine Cervicitis | 1 | 2006 | 7 | 0.270 |
Why?
| | Organizational Policy | 2 | 2019 | 68 | 0.270 |
Why?
| | Prospective Studies | 14 | 2022 | 6217 | 0.270 |
Why?
| | Aged | 18 | 2021 | 19061 | 0.270 |
Why?
| | Aged, 80 and over | 11 | 2021 | 6344 | 0.270 |
Why?
| | Age Factors | 8 | 2016 | 2894 | 0.260 |
Why?
| | Marijuana Use | 2 | 2019 | 167 | 0.260 |
Why?
| | Depression | 4 | 2023 | 1133 | 0.260 |
Why?
| | Perineum | 3 | 2022 | 25 | 0.260 |
Why?
| | Clinical Competence | 3 | 2018 | 893 | 0.250 |
Why?
| | Gelatin | 2 | 2016 | 36 | 0.250 |
Why?
| | Pregnancy Trimester, First | 4 | 2023 | 125 | 0.250 |
Why?
| | Weight Gain | 6 | 2021 | 453 | 0.240 |
Why?
| | Child | 15 | 2023 | 18404 | 0.240 |
Why?
| | Fetal Death | 2 | 2016 | 50 | 0.240 |
Why?
| | Electronics, Medical | 1 | 2004 | 8 | 0.240 |
Why?
| | Laparotomy | 2 | 2015 | 103 | 0.240 |
Why?
| | Telemedicine | 2 | 2023 | 662 | 0.230 |
Why?
| | Database Management Systems | 1 | 2004 | 47 | 0.230 |
Why?
| | Thrombin | 2 | 2016 | 139 | 0.230 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 227 | 0.230 |
Why?
| | Pregnancy Trimester, Second | 4 | 2018 | 66 | 0.230 |
Why?
| | Social Support | 2 | 2020 | 528 | 0.230 |
Why?
| | Aromatherapy | 1 | 2023 | 2 | 0.220 |
Why?
| | Decision Making | 4 | 2016 | 782 | 0.220 |
Why?
| | Birth Weight | 1 | 2006 | 440 | 0.220 |
Why?
| | Cost-Benefit Analysis | 3 | 2020 | 544 | 0.220 |
Why?
| | Pain, Procedural | 1 | 2023 | 12 | 0.220 |
Why?
| | Contraceptive Devices | 1 | 2023 | 1 | 0.220 |
Why?
| | Ethinyl Estradiol | 1 | 2023 | 17 | 0.220 |
Why?
| | House Calls | 2 | 2019 | 115 | 0.220 |
Why?
| | Fertility | 3 | 2023 | 130 | 0.210 |
Why?
| | Patient Health Questionnaire | 1 | 2023 | 21 | 0.210 |
Why?
| | Pain | 2 | 2018 | 705 | 0.210 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 90 | 0.210 |
Why?
| | Attitude of Health Personnel | 2 | 2020 | 975 | 0.210 |
Why?
| | Leuprolide | 1 | 2022 | 19 | 0.210 |
Why?
| | Patient Preference | 2 | 2015 | 167 | 0.210 |
Why?
| | Semen | 1 | 2022 | 18 | 0.210 |
Why?
| | Pregnancy Tests | 2 | 2017 | 7 | 0.200 |
Why?
| | Students, Medical | 2 | 2016 | 262 | 0.200 |
Why?
| | Gestational Age | 4 | 2021 | 759 | 0.200 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2021 | 34 | 0.190 |
Why?
| | Decision Support Techniques | 2 | 2020 | 355 | 0.190 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 18 | 0.190 |
Why?
| | Chorioamnionitis | 1 | 2021 | 36 | 0.190 |
Why?
| | Self Report | 3 | 2021 | 696 | 0.190 |
Why?
| | beta Catenin | 2 | 2022 | 219 | 0.180 |
Why?
| | Lymph Node Excision | 3 | 2018 | 139 | 0.180 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2094 | 0.180 |
Why?
| | Maternal-Child Health Services | 1 | 2020 | 10 | 0.180 |
Why?
| | Parturition | 2 | 2019 | 54 | 0.180 |
Why?
| | Accelerometry | 1 | 2021 | 73 | 0.180 |
Why?
| | Patient Education as Topic | 3 | 2019 | 680 | 0.180 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 1999 | 31 | 0.180 |
Why?
| | Outpatients | 3 | 2023 | 326 | 0.180 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 101 | 0.170 |
Why?
| | Magnetics | 2 | 1999 | 39 | 0.170 |
Why?
| | Obesity | 5 | 2016 | 2507 | 0.170 |
Why?
| | Transgender Persons | 1 | 2022 | 134 | 0.170 |
Why?
| | Dietary Supplements | 1 | 2023 | 460 | 0.170 |
Why?
| | Health Facilities | 1 | 2020 | 72 | 0.170 |
Why?
| | Pharmacogenetics | 1 | 2021 | 149 | 0.170 |
Why?
| | Uterine Hemorrhage | 2 | 2021 | 34 | 0.170 |
Why?
| | Home Health Nursing | 1 | 2019 | 9 | 0.170 |
Why?
| | Medical Oncology | 2 | 2019 | 229 | 0.170 |
Why?
| | Menstruation Disturbances | 1 | 2019 | 12 | 0.170 |
Why?
| | Insulin Resistance | 2 | 2008 | 1072 | 0.170 |
Why?
| | Double-Blind Method | 5 | 2018 | 1660 | 0.170 |
Why?
| | Treatment Outcome | 10 | 2020 | 9084 | 0.170 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 257 | 0.170 |
Why?
| | Neoplasm Staging | 6 | 2020 | 1167 | 0.170 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2017 | 48 | 0.170 |
Why?
| | Databases, Factual | 3 | 2021 | 1124 | 0.170 |
Why?
| | Hysterectomy, Vaginal | 1 | 2019 | 3 | 0.170 |
Why?
| | Cues | 1 | 2022 | 300 | 0.170 |
Why?
| | Cytochrome P450 Family 3 | 1 | 2019 | 2 | 0.160 |
Why?
| | Candidiasis, Vulvovaginal | 1 | 2019 | 4 | 0.160 |
Why?
| | Vaginosis, Bacterial | 1 | 2019 | 11 | 0.160 |
Why?
| | Cancer Pain | 1 | 2019 | 20 | 0.160 |
Why?
| | Live Birth | 1 | 2019 | 48 | 0.160 |
Why?
| | Clothing | 1 | 2019 | 19 | 0.160 |
Why?
| | Hygiene | 1 | 2019 | 27 | 0.160 |
Why?
| | Physician Assistants | 1 | 2020 | 66 | 0.160 |
Why?
| | Anesthesia, Inhalation | 1 | 2018 | 4 | 0.160 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1355 | 0.160 |
Why?
| | Anesthesia, Intravenous | 1 | 2018 | 9 | 0.160 |
Why?
| | Organ Transplantation | 1 | 2021 | 159 | 0.160 |
Why?
| | Anesthetics, Inhalation | 1 | 2018 | 14 | 0.160 |
Why?
| | Nitrous Oxide | 1 | 2018 | 15 | 0.160 |
Why?
| | Anesthetics, Intravenous | 1 | 2018 | 27 | 0.160 |
Why?
| | Nurse Practitioners | 1 | 2020 | 102 | 0.160 |
Why?
| | Pilot Projects | 3 | 2021 | 1372 | 0.150 |
Why?
| | Models, Anatomic | 1 | 2019 | 87 | 0.150 |
Why?
| | Adenocarcinoma | 2 | 2015 | 795 | 0.150 |
Why?
| | Genitalia, Female | 1 | 2018 | 37 | 0.150 |
Why?
| | Ovariectomy | 2 | 2015 | 116 | 0.150 |
Why?
| | Progesterone | 1 | 2019 | 232 | 0.150 |
Why?
| | Databases as Topic | 2 | 2008 | 63 | 0.150 |
Why?
| | Psychometrics | 4 | 2009 | 608 | 0.150 |
Why?
| | Hemostasis, Surgical | 2 | 2016 | 19 | 0.150 |
Why?
| | Oncologists | 1 | 2018 | 31 | 0.150 |
Why?
| | Off-Label Use | 1 | 2018 | 51 | 0.150 |
Why?
| | Culture | 1 | 2019 | 124 | 0.150 |
Why?
| | Risk-Taking | 2 | 2019 | 333 | 0.150 |
Why?
| | Infant, Newborn | 6 | 2021 | 5043 | 0.150 |
Why?
| | Commerce | 1 | 2018 | 61 | 0.150 |
Why?
| | Body Mass Index | 4 | 2019 | 1956 | 0.150 |
Why?
| | Quality of Health Care | 2 | 2021 | 573 | 0.150 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 134 | 0.140 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2018 | 99 | 0.140 |
Why?
| | Sterilization, Reproductive | 1 | 2017 | 6 | 0.140 |
Why?
| | Hysteroscopy | 1 | 2017 | 9 | 0.140 |
Why?
| | Delivery, Obstetric | 4 | 2022 | 118 | 0.140 |
Why?
| | Demyelinating Diseases | 1 | 1998 | 75 | 0.140 |
Why?
| | Incidence | 5 | 2019 | 2311 | 0.140 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2018 | 60 | 0.140 |
Why?
| | Family | 1 | 2021 | 589 | 0.140 |
Why?
| | Ultrasonography | 2 | 2019 | 633 | 0.140 |
Why?
| | Bipolar Disorder | 1 | 1999 | 205 | 0.140 |
Why?
| | Surgeons | 2 | 2018 | 239 | 0.140 |
Why?
| | Infant | 3 | 2023 | 7959 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 7 | 2001 | 3039 | 0.140 |
Why?
| | Follow-Up Studies | 8 | 2019 | 4411 | 0.140 |
Why?
| | Professional-Patient Relations | 1 | 2018 | 141 | 0.140 |
Why?
| | Salpingectomy | 2 | 2015 | 13 | 0.140 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2017 | 31 | 0.140 |
Why?
| | Ambulatory Care | 1 | 2020 | 478 | 0.140 |
Why?
| | Brain Diseases | 1 | 1998 | 124 | 0.140 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 610 | 0.140 |
Why?
| | Minority Groups | 1 | 2018 | 227 | 0.140 |
Why?
| | Abortion, Therapeutic | 1 | 2016 | 5 | 0.140 |
Why?
| | Dilatation and Curettage | 1 | 2016 | 10 | 0.140 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 248 | 0.130 |
Why?
| | Conflict of Interest | 1 | 2018 | 119 | 0.130 |
Why?
| | Pelvic Infection | 1 | 2016 | 4 | 0.130 |
Why?
| | Medical Marijuana | 1 | 2018 | 97 | 0.130 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2017 | 60 | 0.130 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 94 | 0.130 |
Why?
| | Tissue Adhesives | 1 | 2016 | 16 | 0.130 |
Why?
| | Cerebral Cortex | 1 | 1999 | 380 | 0.130 |
Why?
| | Internet | 2 | 2019 | 596 | 0.130 |
Why?
| | Contraception, Postcoital | 1 | 2016 | 6 | 0.130 |
Why?
| | Anticoagulants | 1 | 2020 | 550 | 0.130 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 28 | 0.130 |
Why?
| | Pregnancy, Unwanted | 1 | 2015 | 13 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2021 | 479 | 0.130 |
Why?
| | Patient Compliance | 2 | 2012 | 524 | 0.130 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1998 | 473 | 0.130 |
Why?
| | Risk Factors | 10 | 2022 | 8628 | 0.130 |
Why?
| | Risk Reduction Behavior | 2 | 2014 | 201 | 0.130 |
Why?
| | Curriculum | 3 | 2018 | 819 | 0.130 |
Why?
| | Administration, Cutaneous | 1 | 2015 | 117 | 0.130 |
Why?
| | Interpersonal Relations | 2 | 2017 | 341 | 0.120 |
Why?
| | Placebos | 1 | 2015 | 197 | 0.120 |
Why?
| | Physician-Patient Relations | 2 | 2019 | 462 | 0.120 |
Why?
| | Hot Flashes | 1 | 2015 | 72 | 0.120 |
Why?
| | Contraceptives, Oral | 1 | 2015 | 25 | 0.120 |
Why?
| | Pandemics | 1 | 2023 | 1317 | 0.120 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 150 | 0.120 |
Why?
| | Advanced Practice Nursing | 1 | 2015 | 22 | 0.120 |
Why?
| | Papillomaviridae | 1 | 2015 | 101 | 0.120 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 138 | 0.120 |
Why?
| | Delayed-Action Preparations | 1 | 2015 | 159 | 0.120 |
Why?
| | Prediabetic State | 1 | 2017 | 219 | 0.120 |
Why?
| | Abdominal Abscess | 1 | 2014 | 25 | 0.120 |
Why?
| | Genetic Variation | 1 | 2019 | 870 | 0.110 |
Why?
| | Immunization Schedule | 1 | 2015 | 184 | 0.110 |
Why?
| | Neoplasm Grading | 3 | 2022 | 242 | 0.110 |
Why?
| | Glycoproteins | 1 | 2015 | 304 | 0.110 |
Why?
| | Schizophrenia | 4 | 2000 | 414 | 0.110 |
Why?
| | Fatigue | 1 | 2015 | 294 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 858 | 0.110 |
Why?
| | Endometrium | 1 | 2014 | 60 | 0.110 |
Why?
| | Brain | 8 | 2001 | 2371 | 0.110 |
Why?
| | Otolaryngology | 1 | 2015 | 69 | 0.110 |
Why?
| | Digoxin | 1 | 2013 | 26 | 0.110 |
Why?
| | Logistic Models | 5 | 2019 | 1840 | 0.110 |
Why?
| | Peer Group | 1 | 2015 | 201 | 0.110 |
Why?
| | Overweight | 1 | 2017 | 471 | 0.110 |
Why?
| | Antigens, CD | 1 | 2015 | 442 | 0.110 |
Why?
| | Robotics | 1 | 2014 | 75 | 0.110 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 18 | 0.110 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2013 | 14 | 0.110 |
Why?
| | Motivational Interviewing | 1 | 2014 | 87 | 0.110 |
Why?
| | Umbilical Cord | 1 | 2013 | 80 | 0.110 |
Why?
| | Exercise | 2 | 2021 | 1644 | 0.100 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2013 | 44 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 413 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 329 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1177 | 0.100 |
Why?
| | Analgesics, Opioid | 1 | 2019 | 771 | 0.100 |
Why?
| | Rural Population | 3 | 2022 | 446 | 0.100 |
Why?
| | Papillomavirus Infections | 1 | 2015 | 261 | 0.100 |
Why?
| | Hemorrhage | 1 | 2016 | 620 | 0.100 |
Why?
| | School Health Services | 1 | 2014 | 206 | 0.100 |
Why?
| | Guideline Adherence | 2 | 2021 | 490 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 368 | 0.100 |
Why?
| | Abortion Applicants | 1 | 2010 | 2 | 0.090 |
Why?
| | Glucose Tolerance Test | 2 | 2013 | 343 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2017 | 488 | 0.090 |
Why?
| | Odds Ratio | 2 | 2016 | 953 | 0.090 |
Why?
| | Clinical Clerkship | 1 | 2011 | 72 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 536 | 0.090 |
Why?
| | Health Care Costs | 1 | 2014 | 381 | 0.090 |
Why?
| | Blood Loss, Surgical | 3 | 2016 | 84 | 0.090 |
Why?
| | Domestic Violence | 1 | 2010 | 41 | 0.090 |
Why?
| | Sexual Partners | 2 | 2016 | 161 | 0.090 |
Why?
| | Peptides | 1 | 2015 | 848 | 0.090 |
Why?
| | Sleep | 1 | 2015 | 631 | 0.090 |
Why?
| | Anal Canal | 2 | 2022 | 84 | 0.090 |
Why?
| | Referral and Consultation | 2 | 2018 | 632 | 0.090 |
Why?
| | Neoplasm Invasiveness | 3 | 2017 | 442 | 0.090 |
Why?
| | Risk Assessment | 4 | 2016 | 2967 | 0.090 |
Why?
| | Preoperative Care | 3 | 2017 | 319 | 0.080 |
Why?
| | Research Design | 1 | 2015 | 928 | 0.080 |
Why?
| | Linear Models | 3 | 2019 | 768 | 0.080 |
Why?
| | Latin America | 1 | 2009 | 69 | 0.080 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 44 | 0.080 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2009 | 19 | 0.080 |
Why?
| | Case-Control Studies | 5 | 2020 | 3003 | 0.080 |
Why?
| | Misoprostol | 1 | 2009 | 18 | 0.080 |
Why?
| | Weight Loss | 2 | 2017 | 641 | 0.080 |
Why?
| | Sex Factors | 6 | 2020 | 1715 | 0.080 |
Why?
| | Personality Inventory | 1 | 2009 | 131 | 0.080 |
Why?
| | Interferon-beta | 2 | 2000 | 79 | 0.080 |
Why?
| | Medical Records Systems, Computerized | 1 | 2009 | 88 | 0.080 |
Why?
| | Psychotic Disorders | 2 | 2000 | 118 | 0.080 |
Why?
| | Dominance, Cerebral | 2 | 2000 | 50 | 0.080 |
Why?
| | Pediatrics | 1 | 2016 | 979 | 0.080 |
Why?
| | Breast Feeding | 1 | 2012 | 368 | 0.080 |
Why?
| | Nausea | 2 | 2019 | 101 | 0.080 |
Why?
| | Menarche | 1 | 2008 | 49 | 0.080 |
Why?
| | Smoking | 1 | 2015 | 1380 | 0.080 |
Why?
| | Temporal Lobe | 3 | 1997 | 79 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2012 | 515 | 0.070 |
Why?
| | Schizophrenia, Paranoid | 2 | 1997 | 9 | 0.070 |
Why?
| | Societies, Medical | 3 | 2018 | 663 | 0.070 |
Why?
| | Comorbidity | 2 | 2016 | 1448 | 0.070 |
Why?
| | Reference Values | 3 | 2018 | 742 | 0.070 |
Why?
| | Students, Health Occupations | 1 | 2007 | 23 | 0.070 |
Why?
| | Prognosis | 4 | 2018 | 3328 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 445 | 0.070 |
Why?
| | Length of Stay | 3 | 2015 | 962 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 1998 | 1862 | 0.070 |
Why?
| | Prevalence | 2 | 2017 | 2249 | 0.070 |
Why?
| | Fathers | 1 | 2006 | 45 | 0.070 |
Why?
| | Healthy Volunteers | 2 | 2019 | 197 | 0.070 |
Why?
| | Science | 1 | 2007 | 48 | 0.070 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 87 | 0.070 |
Why?
| | False Positive Reactions | 1 | 2006 | 109 | 0.070 |
Why?
| | Auditory Cortex | 2 | 1997 | 40 | 0.070 |
Why?
| | Maternal Health Services | 1 | 2007 | 79 | 0.070 |
Why?
| | Azithromycin | 1 | 2006 | 80 | 0.060 |
Why?
| | Fatty Liver | 1 | 2008 | 210 | 0.060 |
Why?
| | Urethritis | 1 | 2005 | 3 | 0.060 |
Why?
| | Self Efficacy | 2 | 2019 | 355 | 0.060 |
Why?
| | Uterine Cervical Diseases | 1 | 2005 | 6 | 0.060 |
Why?
| | Teaching | 1 | 2007 | 213 | 0.060 |
Why?
| | Metabolic Syndrome | 1 | 2008 | 321 | 0.060 |
Why?
| | Metformin | 1 | 2008 | 276 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1040 | 0.060 |
Why?
| | Herb-Drug Interactions | 1 | 2023 | 4 | 0.060 |
Why?
| | Acanthosis Nigricans | 1 | 2003 | 6 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2015 | 1121 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2008 | 1342 | 0.060 |
Why?
| | Urban Population | 2 | 2016 | 397 | 0.060 |
Why?
| | Hospitals, University | 2 | 2016 | 172 | 0.060 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2023 | 5 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2177 | 0.050 |
Why?
| | Ovulation | 1 | 2023 | 39 | 0.050 |
Why?
| | Neoplasms | 1 | 2016 | 2097 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2017 | 2387 | 0.050 |
Why?
| | Program Evaluation | 2 | 2019 | 822 | 0.050 |
Why?
| | Anxiety | 2 | 2019 | 840 | 0.050 |
Why?
| | Rifampin | 1 | 2023 | 68 | 0.050 |
Why?
| | Anti-Bacterial Agents | 2 | 2014 | 1477 | 0.050 |
Why?
| | Episiotomy | 1 | 2022 | 2 | 0.050 |
Why?
| | Quality Improvement | 2 | 2022 | 950 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2022 | 108 | 0.050 |
Why?
| | Pregnancy, Twin | 1 | 2021 | 17 | 0.050 |
Why?
| | Travel | 1 | 2022 | 121 | 0.050 |
Why?
| | Biomedical Research | 1 | 2007 | 585 | 0.050 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 33 | 0.050 |
Why?
| | Reproduction | 1 | 2022 | 178 | 0.050 |
Why?
| | Alpha Rhythm | 1 | 2000 | 5 | 0.050 |
Why?
| | Wrist | 1 | 2021 | 48 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2008 | 1008 | 0.040 |
Why?
| | Time-to-Pregnancy | 1 | 2020 | 3 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 45 | 0.040 |
Why?
| | Analysis of Variance | 5 | 2005 | 1226 | 0.040 |
Why?
| | Needs Assessment | 2 | 2015 | 314 | 0.040 |
Why?
| | Mother-Child Relations | 1 | 2021 | 111 | 0.040 |
Why?
| | Coitus | 2 | 2011 | 27 | 0.040 |
Why?
| | Electroencephalography | 2 | 1999 | 362 | 0.040 |
Why?
| | Poverty | 2 | 2017 | 442 | 0.040 |
Why?
| | Ethics, Medical | 1 | 2020 | 70 | 0.040 |
Why?
| | Mutation | 2 | 2022 | 3344 | 0.040 |
Why?
| | Tissue Donors | 1 | 2022 | 316 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2023 | 2762 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2019 | 17 | 0.040 |
Why?
| | Refractory Period, Electrophysiological | 1 | 1999 | 5 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 38 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2019 | 24 | 0.040 |
Why?
| | Median Nerve | 1 | 1999 | 20 | 0.040 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2000 | 69 | 0.040 |
Why?
| | Neural Inhibition | 1 | 2000 | 140 | 0.040 |
Why?
| | Ethics, Institutional | 1 | 2019 | 4 | 0.040 |
Why?
| | Visible Human Projects | 1 | 2019 | 2 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 343 | 0.040 |
Why?
| | Reproductive Health Services | 1 | 2019 | 10 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 31 | 0.040 |
Why?
| | Genital Diseases, Female | 1 | 2019 | 25 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 37 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 32 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 206 | 0.040 |
Why?
| | Operative Time | 1 | 2019 | 106 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 76 | 0.040 |
Why?
| | Pituitary Gland | 1 | 1999 | 148 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 1691 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 68 | 0.040 |
Why?
| | Memory | 2 | 1999 | 211 | 0.040 |
Why?
| | Biological Variation, Population | 1 | 2018 | 19 | 0.040 |
Why?
| | Midazolam | 1 | 2018 | 43 | 0.040 |
Why?
| | Electric Stimulation | 1 | 1999 | 250 | 0.040 |
Why?
| | Hippocampus | 2 | 2001 | 693 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1314 | 0.040 |
Why?
| | Morning Sickness | 1 | 2018 | 4 | 0.040 |
Why?
| | Thalamus | 1 | 1999 | 74 | 0.040 |
Why?
| | Patient Care | 1 | 2019 | 101 | 0.040 |
Why?
| | Fentanyl | 1 | 2018 | 65 | 0.040 |
Why?
| | Psychology, Adolescent | 2 | 2008 | 63 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2000 | 225 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 140 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 304 | 0.040 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 1879 | 0.040 |
Why?
| | Carmustine | 1 | 1998 | 47 | 0.040 |
Why?
| | Frozen Sections | 1 | 2018 | 24 | 0.040 |
Why?
| | Creatine | 1 | 1998 | 50 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2019 | 620 | 0.040 |
Why?
| | Aspartic Acid | 1 | 1998 | 77 | 0.040 |
Why?
| | Transcription Factors | 1 | 2005 | 1528 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2019 | 200 | 0.040 |
Why?
| | Legislation, Drug | 1 | 2018 | 78 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 1998 | 217 | 0.040 |
Why?
| | Hysterosalpingography | 1 | 2017 | 6 | 0.040 |
Why?
| | Sterilization, Tubal | 1 | 2017 | 12 | 0.040 |
Why?
| | Survival Rate | 1 | 2021 | 1644 | 0.040 |
Why?
| | Health Surveys | 1 | 2019 | 443 | 0.040 |
Why?
| | Survival Analysis | 1 | 2020 | 1211 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 1998 | 332 | 0.030 |
Why?
| | Hospitals, Private | 1 | 2016 | 11 | 0.030 |
Why?
| | Cisplatin | 1 | 1998 | 262 | 0.030 |
Why?
| | Health Facility Size | 1 | 2016 | 12 | 0.030 |
Why?
| | Pain Measurement | 1 | 2018 | 444 | 0.030 |
Why?
| | Marijuana Abuse | 1 | 2019 | 212 | 0.030 |
Why?
| | Self Care | 1 | 2019 | 349 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 19 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2016 | 111 | 0.030 |
Why?
| | Marriage | 1 | 2017 | 106 | 0.030 |
Why?
| | Brain Injuries | 1 | 2001 | 461 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 103 | 0.030 |
Why?
| | Radiotherapy | 1 | 2016 | 176 | 0.030 |
Why?
| | Terminal Care | 1 | 2019 | 213 | 0.030 |
Why?
| | Reaction Time | 4 | 2000 | 376 | 0.030 |
Why?
| | Medical Audit | 1 | 2016 | 75 | 0.030 |
Why?
| | Patient Simulation | 1 | 2015 | 29 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2016 | 149 | 0.030 |
Why?
| | Indians, North American | 1 | 2021 | 570 | 0.030 |
Why?
| | North America | 1 | 2016 | 256 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 10 | 0.030 |
Why?
| | Income | 1 | 2016 | 167 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 303 | 0.030 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 151 | 0.030 |
Why?
| | Laparoscopy | 1 | 2019 | 398 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 19 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2006 | 493 | 0.030 |
Why?
| | Competitive Behavior | 1 | 2015 | 39 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2537 | 0.030 |
Why?
| | Female Urogenital Diseases | 1 | 2014 | 5 | 0.030 |
Why?
| | Memory Disorders | 1 | 1996 | 155 | 0.030 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2014 | 25 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 228 | 0.030 |
Why?
| | Morbidity | 1 | 2015 | 280 | 0.030 |
Why?
| | Natural Family Planning Methods | 1 | 2014 | 2 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2015 | 122 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 131 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 23 | 0.030 |
Why?
| | Vagina | 1 | 2016 | 146 | 0.030 |
Why?
| | Homosexuality, Male | 1 | 1995 | 170 | 0.030 |
Why?
| | Disease Progression | 2 | 2017 | 2380 | 0.030 |
Why?
| | Blood Volume | 1 | 2014 | 59 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2016 | 207 | 0.030 |
Why?
| | Educational Measurement | 1 | 2016 | 243 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 90 | 0.030 |
Why?
| | Personnel Selection | 1 | 2015 | 62 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 244 | 0.030 |
Why?
| | Hemostatics | 1 | 2014 | 47 | 0.030 |
Why?
| | Child Development | 1 | 1998 | 385 | 0.030 |
Why?
| | Insulin | 1 | 2003 | 2076 | 0.030 |
Why?
| | Acoustic Stimulation | 3 | 2000 | 314 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 1879 | 0.030 |
Why?
| | Drainage | 1 | 2014 | 151 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2015 | 319 | 0.030 |
Why?
| | Cesarean Section | 1 | 2015 | 169 | 0.030 |
Why?
| | Administration, Intravaginal | 1 | 2013 | 20 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1998 | 1842 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1430 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 718 | 0.030 |
Why?
| | Patient Readmission | 1 | 2018 | 609 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 372 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1018 | 0.030 |
Why?
| | Alcoholism | 1 | 1999 | 713 | 0.030 |
Why?
| | Biomarkers | 1 | 2023 | 3408 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 1998 | 376 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 1998 | 520 | 0.030 |
Why?
| | Perception | 1 | 2015 | 311 | 0.030 |
Why?
| | Escherichia coli | 1 | 2016 | 720 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2014 | 539 | 0.030 |
Why?
| | Text Messaging | 1 | 2014 | 152 | 0.020 |
Why?
| | Specialty Boards | 1 | 2011 | 32 | 0.020 |
Why?
| | Registries | 1 | 2019 | 1767 | 0.020 |
Why?
| | Phenotype | 1 | 1999 | 2796 | 0.020 |
Why?
| | Faculty | 1 | 2011 | 130 | 0.020 |
Why?
| | Medicaid | 1 | 2014 | 406 | 0.020 |
Why?
| | Physicians | 1 | 2018 | 772 | 0.020 |
Why?
| | Students | 1 | 2014 | 501 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1578 | 0.020 |
Why?
| | Interferon beta-1a | 2 | 2000 | 12 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2353 | 0.020 |
Why?
| | New York City | 1 | 2009 | 70 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2011 | 582 | 0.020 |
Why?
| | Urban Health Services | 1 | 2009 | 60 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 2710 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 771 | 0.020 |
Why?
| | Injections, Intramuscular | 2 | 2000 | 116 | 0.020 |
Why?
| | Gravidity | 1 | 2008 | 7 | 0.020 |
Why?
| | Aging | 1 | 1998 | 1618 | 0.020 |
Why?
| | Southwestern United States | 1 | 2008 | 91 | 0.020 |
Why?
| | Cross-Cultural Comparison | 1 | 2008 | 77 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 9108 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 1749 | 0.020 |
Why?
| | Diet | 1 | 2014 | 1080 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2008 | 183 | 0.020 |
Why?
| | Social Perception | 1 | 2008 | 95 | 0.020 |
Why?
| | Puberty | 1 | 2008 | 135 | 0.020 |
Why?
| | Urine | 1 | 2007 | 54 | 0.020 |
Why?
| | Forecasting | 1 | 2008 | 330 | 0.020 |
Why?
| | Urinalysis | 1 | 2007 | 64 | 0.020 |
Why?
| | Medical Indigency | 1 | 2006 | 11 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2362 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2007 | 106 | 0.020 |
Why?
| | Education | 1 | 2007 | 95 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2008 | 243 | 0.020 |
Why?
| | Social Environment | 1 | 2008 | 283 | 0.020 |
Why?
| | Research Support as Topic | 1 | 2007 | 108 | 0.020 |
Why?
| | Triglycerides | 1 | 2008 | 467 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2279 | 0.020 |
Why?
| | Universities | 1 | 2007 | 339 | 0.010 |
Why?
| | Sex Characteristics | 2 | 1999 | 640 | 0.010 |
Why?
| | Attention | 2 | 1999 | 393 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 42 | 0.010 |
Why?
| | Self Concept | 1 | 2005 | 213 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2005 | 321 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2005 | 1075 | 0.010 |
Why?
| | Research | 1 | 2005 | 394 | 0.010 |
Why?
| | Blood Pressure | 1 | 2008 | 1538 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 2 | 1997 | 682 | 0.010 |
Why?
| | Electromagnetic Fields | 1 | 1999 | 21 | 0.010 |
Why?
| | Blood Glucose | 1 | 2008 | 1819 | 0.010 |
Why?
| | Schizophrenic Psychology | 1 | 1999 | 86 | 0.010 |
Why?
| | Cognition | 1 | 2005 | 988 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1998 | 52 | 0.010 |
Why?
| | Gadolinium | 1 | 1998 | 73 | 0.010 |
Why?
| | Sound Localization | 1 | 1998 | 64 | 0.010 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 1999 | 222 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 497 | 0.010 |
Why?
| | Least-Squares Analysis | 1 | 1995 | 70 | 0.010 |
Why?
| | Confidence Intervals | 1 | 1996 | 305 | 0.010 |
Why?
| | Verbal Behavior | 1 | 1995 | 43 | 0.010 |
Why?
| | Space Perception | 1 | 1995 | 64 | 0.010 |
Why?
| | Software | 1 | 1999 | 529 | 0.010 |
Why?
| | Cognition Disorders | 1 | 1999 | 476 | 0.010 |
Why?
| | Recurrence | 1 | 1998 | 935 | 0.010 |
Why?
|
|
Sheeder's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|